Enteric Coated Mycophenolate Sodium

Phase 3

Enteric Coated Mycophenolate Sodium is one of 5 therapeutic programs targeting Renal Allograft Recipients. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Renal Allograft RecipientsRecruiting

Renal Allograft RecipientsPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Renal Allograft Recipients

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 3

2 2

Nulojix

Bristol-Myers Squibb

Phase 3

1 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

5 4

Cyclosporine a

Novartis

Phase 3

1 5

Enteric Coated Mycophenolate Sodium

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 3Recruiting

Renal Allograft Recipients

NCT04877288

Clinical

Trials by Indication[1]

Renal Allograft Recipients1 trial

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04877288·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enteric Coated Mycophenolate Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Enteric Coated Mycophenolate Sodium. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Enteric Coated Mycophenolate Sodium

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2034

Trials by Indication[1]

Renal Allograft Recipients1 trial

References

Drug Info

Quick Facts

Related News